HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GMO Evolution Creates Challenges For ‘Clean Label’ Supplement Marketers

Executive Summary

Supplement and food firms should "check to see if any ingredients they use may be affected or potentially contaminated by genetically engineered bio-synthesized ingredients,” said Jim Thomas, scientist and co-founder of ETC Group. Biotechnologies have emerged to yield ingredients for clean label products with organisms raised in ecosystems developed from processes that involve genetic engineering.

You may also be interested in...



COVID-19 Deter Class Actions? No. Plaintiffs' Attorneys Have Time For More Complaints? Yes.

Class action complaints filed in 2020 against food, dietary supplement and beverage firms should pass 2019’s total as COVID-19 has not slowed litigants but has given plaintiffs’ council more time out of court to shop for new cases.

Waiting For FDA: Federal Courts Debate Stays Of 'Natural' Class Actions

Mayer Brown attorney Dale Giali discusses the "natural" litigation landscape, where litigants increasingly are sparring over the appropriateness of stays in light of FDA's comment-gathering initiative launched in 2015.

GMO Labeling Advocates Pivot To Pitching Economic Sense

Labeling advocates at Natural Products Expo East vow to maintain fight against GMOs by encouraging companies against GMO use. Just Label It! and the Non-GMO Project reps say they also will seek to provide input to USDA in drafting labeling rules.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148837

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel